deltatrials
Completed PHASE1/PHASE2 NCT00041808

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (Via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the Liver .

Sponsor: FeRx

Conditions Breast Neoplasms Cholangiocarcinoma Colorectal Neoplasms Esophageal Neoplasms Gastrointestinal Neoplasms Liver Neoplasms Lung Neoplasms Melanoma Metastases, Neoplasm Pancreatic Neoplasms Sarcoma Stomach Neoplasms
Interventions Chemotherapy MTC-DOX for Injection
Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Jul 31, 2001 Completion: Apr 30, 2003

This PHASE1/PHASE2 trial investigates Breast Neoplasms and Cholangiocarcinoma and is currently completed. FeRx leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jul 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • FeRx
Data source: FeRx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Frankfurt, Germany
  • • San Diego, United States
  • • San Francisco, United States
  • • Temple, United States